Posted by Fred Dunkley
Share on Facebook
Tweet on Twitter
The announcement last week that Bristol-Myers Squibb will acquire drugmaker Celgene in a $74-billion deal is a big bet on a line-up of cancer drugs as 2019 ushers in a push to raise the price of over 1,000 medications and earns the industry a great deal of scrutiny in Washington.
Shares of Celgene spiked on the news Thursday, while Bristol’s flopped…. CLICK for complete article
I know Mike is a very solid investor and respect his opinions very much. So if he says pay attention to this or that - I will.
~ Dale G.
I've started managing my own investments so view Michael's site as a one-stop shop from which to get information and perspectives.
~ Dave E.
Michael offers easy reading, honest, common sense information that anyone can use in a practical manner.
~ der_al.
A sane voice in a scrambled investment world.
~ Ed R.
Greg Weldon
Josef Schachter
Tyler Bollhorn
Ryan Irvine
Paul Beattie
Martin Straith
Patrick Ceresna
Mark Leibovit
James Thorne
Victor Adair